Bulk Drug Manufacturing Regulatory : Industry Panel Moderated by Santosh Savarkar

In this comprehensive panel discussion, leading regulatory executives and industry experts gather to examine the rapidly shifting regulatory landscape governing bulk drug and Active Pharmaceutical Ingredient (API) manufacturing. Moderated by Santosh Savarkar, Director at RBridge Lifesciences Pvt Ltd, this high-level session dives deep into the strategic, operational, and technical aspects of supplying high-quality bulk active ingredients to highly regulated global markets. The panellists analyse critical topics including chemistry, manufacturing, and controls (CMC) compliance; Drug Master File (DMF) and Abbreviated New Drug Application (ANDA) approval strategies; health authority query responses; and the implementation of robust quality management systems that meet evolving international standards set by global regulators such as the US FDA, EMA, and WHO. Throughout the discussion, the panel explores how pharmaceutical companies can build an integrated, proactive regulatory framework that bridges scientific innovation, Good Manufacturing Practice (GMP) standards, and supply chain security. By highlighting real-world lessons from API manufacturing operations, risk mitigation strategies, and health authority inspection readiness, this interactive dialogue provides regulatory affairs professionals, quality heads, supply chain leaders, and pharmaceutical executives with practical solutions to overcome compliance hurdles, streamline dossier approvals, and ensure patient safety worldwide. Santosh Savarkar serves as Director at RBridge Lifesciences Pvt Ltd, bringing over three decades of deep technical and strategic leadership in pharmaceutical regulatory affairs, international compliance, and quality systems. Known for his expertise in guiding organisations through complex regulatory submissions, technical due diligence, gap analysis, and global health authority inspections, Santosh adeptly steers the panel through critical industry themes, synthesising diverse expert viewpoints into actionable operational takeaways for modern bulk drug manufacturing enterprises. #Pharmaceuticals #BulkDrugs #APIManufacturing #RegulatoryAffairs #PharmaCompliance #GMP #CMC #RBridgeLifesciences #SantoshSavarkar #LifeSciences #PharmaPanel #DrugSafety